Halozyme Therapeutics Inc
NASDAQ:HALO

Watchlist Manager
Halozyme Therapeutics Inc Logo
Halozyme Therapeutics Inc
NASDAQ:HALO
Watchlist
Price: 69.5414 USD -2.45% Market Closed
Market Cap: $8.2B

Net Margin

47.9%
Current
Improving
by 10.1%
vs 3-y average of 37.8%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
47.9%
=
Net Income
$595.5m
/
Revenue
$1.2B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
47.9%
=
Net Income
$595.5m
/
Revenue
$1.2B

Peer Comparison

Country Company Market Cap Net
Margin
US
Halozyme Therapeutics Inc
NASDAQ:HALO
8.2B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Higher than 96% of companies in the United States of America
Percentile
96th
Based on 15 072 companies
96th percentile
47.9%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Halozyme Therapeutics Inc
Glance View

Halozyme Therapeutics Inc., a California-based biopharmaceutical company, weaves innovation with practicality in the realm of drug delivery. The narrative of Halozyme is centered around its proprietary enzyme technology, known as ENHANZE®. This platform is a transformative approach that leverages a recombinant human hyaluronidase enzyme, named rHuPH20. This enzyme temporarily degrades hyaluronan, a key component in the extracellular matrix, thereby allowing for quicker dispersal and absorption of subcutaneous drugs. By facilitating the transition of therapies from intravenous to subcutaneous administration, Halozyme not only enhances the patient experience with less clinic time and reduced infusion-related costs but also provides pharmaceutical partners with the opportunity to extend the lifecycle of their drugs. The company’s revenue generation resembles a carefully orchestrated symphony, harmonizing collaboration and licensing agreements with prominent pharmaceutical giants such as Roche and Bristol-Myers Squibb. Halozyme earns through a blend of upfront licensing fees, milestone payments, and royalties on product sales that incorporate the ENHANZE® technology. These alliances empower its partners to broaden the utility of their existing drug formulations, while Halozyme benefits from a steady cash inflow that supports its ongoing research and development activities. In essence, Halozyme’s business model thrives on creating value by enhancing drug delivery mechanisms, ensuring that its innovations are profitable not only for the partners it collaborates with but also for patients worldwide who benefit from its advancements.

HALO Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
47.9%
=
Net Income
$595.5m
/
Revenue
$1.2B
What is Halozyme Therapeutics Inc's current Net Margin?

The current Net Margin for Halozyme Therapeutics Inc is 47.9%, which is above its 3-year median of 37.8%.

How has Net Margin changed over time?

Over the last 3 years, Halozyme Therapeutics Inc’s Net Margin has increased from 36.4% to 47.9%. During this period, it reached a low of 25.8% on Mar 31, 2023 and a high of 47.9% on Sep 30, 2025.

Back to Top